New Delhi: The Central Drugs Standard Control Organization (CDSCO) has identified 94 batches of medicines and medical products as "Not of Standard Quality" (NSQ) after samples tested in September 2025 by its central and state laboratories failed to meet required pharmacopeial and safety standards.

The flagged products cover a wide range of therapeutic categories, including antibiotics, analgesics, antipyretics, antidiabetics, and other essential medicines.

These include Glimepiride Tablets IP 1 mg, manufactured by Karnataka Antibiotics and Pharmaceuticals, Telmisartan tab I.P. 40 mg, manufactured by Helax Healthcare, Bromhexine Hydrochloride Tablets IP 4 mg, manufactured by J.P. Industries, Rabeprazole Sodium Injection IP, manufactured by Martin & Brown Bio-Sciences, Dexamethasone Injec

See Full Page